stockrowvTv Therapeutics Inc.
VTVT Healthcare Biotechnology
vTv Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, down 49.6% from fiscal 2022.
- Revenue
- +409,222.2%
- EPS
- −14.1%
- Free cash flow
- −124.6%
Quarter to June 2026, against a year earlier
Follow VTVT
Alert me
vTv Therapeutics Inc. (VTVT) EV/Sales
As of 6 November 2026, vTv Therapeutics Inc. (VTVT) trades at a EV/Sales of 4.7×. Over the past ten years it has ranged from −73.7× (March 2016) to 4,969× (December 2020); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 42.8× | 93.58% |
| FY2022 | 22.1× | 76.20% |
| FY2021 | 12.6× | (3.23%) |
| FY2020 | 13.0× | (29.81%) |
| FY2019 | 18.5× | 510.61% |
| FY2018 | 3.0× | (98.58%) |
| FY2017 | 214× | 1,685.89% |
| FY2016 | 12.0× | — |
| FY2015 | −48.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 10.4× | (75.61%) |
| Dec 2024 | 42.8× | 141.71% |
| Mar 2024 | 17.7× | (19.91%) |
| Dec 2022 | 22.1× | 205.96% |
| 29 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SEER Seer, Inc. compare | −4.4× |
| MIST Milestone Pharmaceuticals Inc. compare | −1.1× |
| RLYB Rallybio Corporation compare | −0.8× |
| PLYX Polaryx Therapeutics, Inc. compare | n/m |
| EQ Equillium, Inc. compare | 2.9× |
| VTVT vTv Therapeutics Inc. | 4.7× |
| GNLX Genelux Corporation compare | 7.0× |
| CBUS Cibus, Inc. compare | 16.2× |
| RTSN Retension Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)